JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
(the Company), issued a press release announcing financial
results for the three months ended March 31, 2017. A copy of the
press release is being furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
Form 8-K (including Exhibit 99.1) shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued by the Company on May 9, 2017
|
About JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE)
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody. JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) Recent Trading Information
JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) closed its last trading session 00.00 at 24.62 with 80,691 shares trading hands.